What is HIPEC?
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a highly concentrated, heated chemotherapy treatment that is delivered directly to the abdomen during surgery.
Unlike systemic chemotherapy delivery, which circulates throughout the body, HIPEC delivers chemotherapy directly to cancer cells in the abdomen. This allows for higher doses of chemotherapy treatment. Heating the solution may also improve the absorption of chemotherapy drugs by tumors and destroy microscopic cancer cells that remain in the abdomen after surgery.
How it works
Before patients receive HIPEC treatment, doctors perform cytoreductive surgery to remove visible tumors within the abdomen. Cytoreductive surgery is accomplished using various surgical techniques. Once as many tumors as possible have been removed, the heated, sterilized chemotherapy solution is delivered to the abdomen to penetrate and destroy remaining cancer cells. The solution is 41 to 42 degrees Celsius, about the temperature of a warm bath. It’s circulated throughout the abdomen for approximately 1 ½ hours. The solution is then drained from the abdomen and the incision is closed.
HIPEC is a treatment option for people who have advanced surface spread of cancer within the abdomen, without disease involvement outside of the abdomen.
Advantages of HIPEC
- Allows for high doses of chemotherapy
- Enhances and concentrates chemotherapy within the abdomen
- Minimizes the rest of the body’s exposure to the chemotherapy
- Improves chemotherapy absorption and susceptibility of cancer cells
- Reduces some chemotherapy side effects
Contact us at 800-515-9608 to learn more about our HIPEC program and team of experts.
Meet our team of HIPEC experts
Our Centers for Peritoneal Surface Malignancies offer cytoreductive surgery and HIPEC for advanced stage abdominal cancers, including appendiceal (appendix) cancer, colorectal cancer, primary peritoneal cancer, peritoneal mesothelioma, ovarian cancer and stomach cancer.
Our HIPEC experts are surgical oncologists who have several years of experience in performing complex and advanced surgical procedures. They work with a multispecialty team that includes medical oncologists, radiation oncologists and radiologists. The team offers each patient a comprehensive and personalized cancer treatment plan. Patients' care teams also include clinical oncology dietitians, pain management clinicians, naturopathic oncology providers, mind-body therapists, physical therapists and spiritual counselors to help patients manage treatment side effects and improve quality of life.
Referring physicians: To refer a patient or for assistance in determining if your patient is a candidate for HIPEC, please contact Julie Christensen, our HIPEC coordinator, directly at 847-731-1687 or Julie.Christensen@ctca-hope.com.
Learn about our HIPEC experts:
Hatem Halabi, MD, FACS
Midwestern Regional Medical Center (suburban Chicago)
Dr. Halabi earned a medical degree at the American University in Beirut. He completed a general surgery internship and residency, in addition to a fellowship in surgery, medical informatics and telemedicine at the Medical College of Virginia in Richmond. He completed a surgical oncology fellowship at The Institute for Cancer Care at Mercy Health Services in Baltimore. Furthermore, Dr. Halabi studied translational research in clinical oncology at the National Cancer Institute in Bethesda, Maryland.
Read Dr. Halabi's full bio
HIPEC for soft tissue sarcoma
For soft tissue sarcomas located in the abdomen or uterus such as liposarcomas and pleomorphic undifferentiated sarcomas, HIPEC may be an appropriate treatment option.
Although gastrointestinal stromal tumors (GISTs) occur in the digestive system, these tumors do not respond well to standard chemotherapy. Patients with GISTs are not likely to benefit from soft tissue sarcoma HIPEC treatment.